Safety and efficacy of neoadjuvant hormone therapy with combination of Estramustine Phosphate Sodium Hydrate and LH-RH agonist for high-risk prostate cancer treated with intensity modulated radiotherapy
Not Applicable
- Conditions
- prostate cancer
- Registration Number
- JPRN-UMIN000027581
- Lead Sponsor
- Tohoku University
- Brief Summary
This study was terminated because there were not any enrolled cases.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- Male
- Target Recruitment
- 0
Inclusion Criteria
Not provided
Exclusion Criteria
1)patinets with another active cancers 2)patinets with severe cardiovascular diseases and diabetis militus 3)patients treated with 5a-reductase inhibitors for prostate hyperplasia 4)patientes treated with adrenocortical steroids 5)patinets with another anticancer agents 6)patients ineligible for this study judged by investigators
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method